---
title: "Enfortumab vedotin shows increased activity in cisplatin‑resistant HT1376 bladder cancer model"
id: "plos-one-20-enhanced-enfortumab-vedotin-sensitivity-in-a-cisplatin-resistant-bladder-cancer"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-20-enhanced-enfortumab-vedotin-sensitivity-in-a-cisplatin-resistant-bladder-cancer"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0361593"
published_at: "2026-10-29T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Enfortumab vedotin shows increased activity in cisplatin‑resistant HT1376 bladder cancer model
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-20-enhanced-enfortumab-vedotin-sensitivity-in-a-cisplatin-resistant-bladder-cancer
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0361593)
- **Published At:** 2026-10-29T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators created a cisplatin (CDDP)-resistant bladder cancer subline, HT1376-CR, by stepwise exposure to increasing CDDP concentrations until a final culture concentration of 1.5 µg/mL was reached. The cohort showed faster in vitro proliferation than the parental HT1376/P line. - The team compared sensitivities to **cisplatin**, **enfortumab vedotin** (EV), and the ADC payload **MMAE** using cell viability assays; IC50 values were calculated from three independent experiments. - Data indicated HT1376-CR had over threefold higher IC50 for CDDP versus HT1376/P, confirming acquired CDDP resistance; investigators reported markedly enhanced sensitivity of HT1376-CR to EV in vitro across tested concentrations. - In a xenograft model (subcutaneous HT1376/P and HT1376-CR tumors in BALB/c nude mice), weekly intraperitoneal EV (1 mg/kg) for three weeks reduced tumor growth in both models; two-way ANOVA of log-transformed RTV at day 22 showed a statistically significant interaction between tumor model and treatment (p = 0.039), indicating differential antitumor efficacy. - Flow cytometry and immunoblotting showed reduced cell-surface and total **nectin-4** expression and decreased EV binding in HT1376-CR compared with parental cells, despite the increased EV sensitivity. - HT1376-CR cells were more sensitive to **MMAE** and exhibited greater G2/M cell-cycle accumulation after MMAE exposure, suggesting increased payload susceptibility contributes to EV efficacy. - Quantitative PCR and immunoblotting revealed marked upregulation of **ABCB1** in HT1376-CR. RNA interference targeting ABCB1 restored sensitivity to CDDP, MMAE, and EV within the resistant subline, as shown by cell viability assays. - The study reported methods in detail (cell culture conditions, viability assays, flow cytometry, western blotting, xenograft procedures, and statistical analysis). Investigators noted data and original immunoblots are provided in supporting files. - The report did not provide broader clinical dosing recommendations, patient-level data, or long-term toxicity outcomes; it focused on mechanistic and preclinical efficacy comparisons between parental and CDDP-resistant models.
## Clinical Analysis & Structured Key Points
Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Objective Enfortumab vedotin (EV) and cisplatin (CDDP) are central treatments for advanced urothelial carcinoma, yet the influence of prior CDDP exposure on subsequent EV efficacy remains unclear. In this report, we characterized EV-related drug responses in a CDDP-resistant bladder cancer subline. Methods A CDDP-resistant subline (HT1376-CR) was generated from parental bladder cancer cell (HT1376/P) through continuous exposure to CDDP. Sensitivities to CDDP, EV, and the EV payload monomethyl auristatin E (MMAE) were compared between HT1376-CR and HT1376/P. Nectin-4 expression, EV binding, and drug-resistance-related gene expression were evaluated. The effect of ABCB1 silencing on drug response was also examined. In vivo EV responses were explored using xenograft models. Results HT1376-CR cells showed increased sensitivity to EV in vitro and in vivo. HT1376-CR cells were more sensitive to MMAE and showed greater G2/M accumulation after MMAE exposure. In contrast, cell-surface nectin-4 expression and EV binding were reduced. ABCB1 was markedly upregulated in HT1376-CR, and ABCB1 silencing increased sensitivity to CDDP, MMAE, and EV within the resistant subline. Conclusion The CDDP-resistant HT1376 subline showed enhanced sensitivity to EV, and ABCB1 suppression further increased EV sensitivity within this resistant subline. Citation: Tobe T, Teishima J, Hara T, Shiraishi Y, Ueki H, Wakita N, et al. (2026) Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model. PLoS One 21(10): e0361593. https://doi.org/10.1371/journal.pone.0361593 Editor: Satish Rojekar, Icahn School of Medicine at Mount Sinai Department of Pharmacological Sciences, UNITED STATES OF AMERICA Received: February 10, 2026; Accepted: October 13, 2026; Published: October 29, 2026 Copyright: © 2026 Tobe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: All relevant data are within the manuscript and its Supporting Information files. Funding: The author(s) received no specific funding for this work. Competing interests: The authors have declared that no competing interests exist. Introduction Bladder cancer is among the most common malignancies worldwide, with approximately 430,000 new cases diagnosed annually, ranking as the 11 th most frequent cancer globally [ 1 ]. Although treatment options have expanded in recent years, the prognosis for patients with advanced bladder cancer remains poor, highlighting the urgent need for more effective systemic therapies. For patients with locally advanced or metastatic urothelial carcinoma, systemic therapy has been the cornerstone of disease management. Historically, cisplatin (CDDP)-based combination chemotherapy has served as the standard of care. In recent years, however, the therapeutic landscape has evolved dramatically with the advent of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs). Among the latter, enfortumab vedotin (EV) has emerged as a pivotal therapeutic agent. EV exerts its antitumor effect by binding to nectin-4, followed by internalization into tumor cells, where its cytotoxic payload, monomethyl auristatin E (MMAE), disrupts microtubule dynamics [ 2 ]. EV is now used either in combination with pembrolizumab as a first-line regimen or as a monotherapy following platinum-based therapy [ 3 , 4 ]. Despite these advances, platinum-based chemotherapy continues to play a critical role, particularly in regimens such as CDDP plus gemcitabine combined with nivolumab, and remains indispensable for patients ineligible for ICIs [ 5 ]. Consequently, the current therapeutic paradigm often relies on platinum-based chemotherapy followed by EV as a subsequent-line therapy. However, the impact of prior exposure to platinum on subsequent EV efficacy remains unresolved. Reduced nectin-4 expression has been reported in cisplatin-resistant cells [ 6 ], and in breast cancer models, ABC transporter B family member 1 (ABCB1, P-glycoprotein/multidrug resistance 1) upregulation has been implicated in resistance to nectin-4-targeted ADCs [ 7 ]. These observations raise the possibility that acquired CDDP resistance may be accompanied by changes relevant to EV response. In this study, we established a CDDP-resistant bladder cancer subline and compared the sensitivities of the parental and CDDP-resistant cell lines to CDDP, EV, and MMAE. We also characterized nectin-4 expression, EV binding, and ABC transporter expression associated with the acquisition of cisplatin resistance. Materials and Methods Cell culturing The human bladder cancer cell line HT1376 (ATCC, CRL-1472) was cultured in Eagle's Minimum Essential Medium (FUJIFILM Wako Pure Chemical Corporation, 051–076615) supplemented with 10% fetal bovine serum (BIOSERA, FB-1003/500) at 37 °C in a humidified atmosphere of 5% CO 2 . Stable CDDP-resistant HT1376 cell lines were established by stepwise exposure to increasing concentrations of CDDP (FUJIFILM Wako Pure Chemical Corporation, 039–20093), starting at 0.01 µg/mL and progressively increasing at each passage until a final resistance concentration of 1.5 µg/mL was reached. Cell viability assay Cells (1.0 × 10³ per well) were seeded into 96-well plates and treated with CDDP, EV (Selleck, D4053), or MMAE (Selleck, S7721). Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) reagent (Dojindo, CK04) 3 days after CDDP or MMAE treatment, and 5 days after EV treatment. Plates were incubated with CCK-8 reagent for 2 h in the dark, and the absorbance was measured at 450 nm using a Varioskan LUX microplate reader (Thermo Fisher Scientific). IC 50 values were determined by nonlinear regression using a four-parameter logistic model in GraphPad Prism (version 10.5.0). Data are presented as the standard error of the mean (SEM) from three independent experiments ( n = 3). Cell proliferation Cells (1 × 10³ per well) were seeded into 96-well culture plates in 100 µl of medium and cultured for 1, 2, 3, 4, or 5 days. Cell proliferation was quantified using CCK-8, as described above. Absorbance values at each time point were normalized to the day‑1 measurements for the corresponding conditions to yield relative proliferation. Data are presented as the mean ± SEM from three independent experiments ( n = 3). Western blotting Cells were washed in PBS and lysed with RIPA buffer (FUJIFILM Wako Pure Chemical Corporation, 182−02451) supplemented with a protease inhibitor cocktail (Roche, 05892791001). Protein concentrations were determined using the BCA Protein Assay kit (Thermo Fisher, 23225). Lysates were mixed with 4× Laemmli Sample Buffer (Bio-Rad, #1610747) containing 2-mercaptoethanol (Sigma-Aldrich, M3148) and boiled at 95 °C for 5 min. Proteins were separated by SDS-PAGE and transferred to PVDF membranes (Merck, IPVH00010). Membranes were blocked with 5% skim milk in PBS-T (0.05% Tween 20) and incubated overnight with the primary antibodies: anti-nectin-4 (Abcam, ab235897), anti-ABCB1 (Cell Signaling Technology, E1Y7S), and anti-β-actin (Abcam, ab227387). The following day, membranes were washed with PBS-T and incubated with a horseradish peroxidase-conjugated secondary antibody (Abcam, ab7090) for 1 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence detection reagent (Cytiva, RPN2232) and quantified using an Amersham Imager 600 system (Cytiva). Data are presented as the mean ± SEM from three independent experiments ( n = 3). Flow Cytometry HT1376/P and HT1376-CR cells were seeded in culture plates and detached using enzyme-free cell dissociation solution (Sigma-Aldrich, C5789). To assess cell surface nectin-4 expression, cells were incubated with an anti-nectin-4 antibody (R&D systems, FAB2659P) or isotype control antibody (R&D systems, IC0041P) for 30 min at 4 °C. Flow cytometric analysis was performed using a CytoFLEX flow cytometer (Beckman Coulter), and mean fluorescence intensity (MFI) was quantified using FlowJo software (BD Biosciences). Relative nectin-4 expression was determined by subtracting the MFI of the control antibody from that of the anti-nectin-4 antibody. To evaluate the binding of EV to the cell surface, cells were incubated with EV (3.3 or 13.2 nM) for 30 min at 4 °C, followed by incubation with APC anti-human IgG Fc antibody (BioLegend, 410711) for an additional 30 min at 4°C. Samples were analyzed using the same procedure described above. Quantitative real-time PCR Total RNA was extracted from cell lines using TRIzol reagent (Invitrogen, 15596026) according to the manufacturer’s instructions. The RNA concentration and purity were assessed using a NanoDrop One spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized using a reverse transcription kit (Thermo Fisher Scientific, 11766050) according to the manufacturer’s protocol. Quantitative PCR was performed using SYBR Green Master Mix (TOYOBO, QPX-201). Primer sequences used for PCR are listed in S1 Table . Data are presented as the mean ± SEM from three independent experiments ( n = 3). Cell cycle assay HT1376/P and HT1376-CR cells were seeded at a density of 2 × 10 5 cells per well. After 24 h, the cells were exposed to MMAE (0.0 or 2.0 nM) for an additional 24 h. Cells were harvested, stained with Cell Cycle Assay Solution Deep Red Kit (Dojindo, C548), and analyzed by flow cytometry (Beckman Coulter, CytoFLEX). Cell cycle distribution (G1, S, and G2/M phases) was assessed using FlowJo software (BD Biosciences). RNA interference HT1376-CR cells were transfected with ABCB1 siRNA (Thermo Fisher Scientific, s10418 and s10419). A non-targeting siRNA (Thermo Fisher Scientific, 94566) served as the negative control. Cells (2 × 10 5 per well) were seeded in 6-well plates and transfected the following day using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific, 13778030), according to the manufacturer’s protocol. Xenograft tumor growth Female BALB/c nude mice (8 weeks old, body weight 26–28 g) were subcutaneously injected with HT1376/P or HT1376-CR cells (3 × 10 6 ) into the flank. When the longest tumor diameter reached 10 mm, mice were randomly assigned to receive either EV (1 mg/kg) or vehicle control (physiological saline) by intraperitoneal injection once weekly for 3 weeks. Tumor length (the longest diameter) was measured with a caliper. For volume calculation, tumor width was approximated as half of the length (width = length/2), and tumor volumes were calculated using the formula length × width 2 × π/6. After 21 days of treatment, mice were deeply anesthetized with isoflurane. After confirming death by cessation of respiration, tumors were excised and weighed. Both the length and width of each excised tumor were directly measured, and terminal tumor volume was calculated using the formula length × width² × π/6. Tumors were subsequently fixed in 4% paraformaldehyde. Relative tumor volume (RTV) was calculated for each mouse by dividing the tumor volume on day 22 by the tumor volume on day 1. RTV values are presented as mean ± SEM for each group. Because death or severe deterioration of animal health could potentially occur as a result of tumor progression or drug treatment, predefined humane endpoints were established prior to initiation of the study. Animals were euthanized at any time during the experimental period if any of the following criteria were observed: severe adverse effects related to drug administration, including marked inflammation or secondary infection; impaired mobility, such as persistent recumbency or crouching posture; or signs of organ or tissue damage, including dyspnea or labored breathing, symptoms of shock, diarrhea or vomiting, seizures, or circling behavior. In addition, animals were euthanized if body weight loss exceeded 20% compared with control animals or if body weight loss of 25% or more was observed within a 7-day period. Euthanasia was performed by overdose of isoflurane anesthesia. Animal health status and behavior were monitored twice weekly throughout the experimental period, which lasted approximately three months from tumor cell inoculation to study completion. A total of 14 mice were used in this study. All animals were euthanized at the experimental endpoint. None of the animals met the humane endpoint criteria prior to the planned experimental endpoint, and therefore no mice were euthanized prematurely due to adverse treatment effects. Animal experiments in this study were approved by Kobe University (approval number P-250503). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal procedures were performed by personnel who were appropriately trained and certified in laboratory animal care and handling, in accordance with institutional guidelines. Statistical analysis Continuous variables in experimental data are reported as means with 95% confidence intervals. Group comparisons were performed using Student’s t -test for continuous variables. To determine whether the antitumor effect of EV differed between tumor models, RTV values were analyzed by two-way ANOVA with factors for tumor model (HT1376/P vs HT1376-CR), treatment (EV vs vehicle). For all statistical analyses, P < 0.05 was considered statistically significant. In all figures, statistical significance is denoted as follows: ns, ≥ 0.05; *, 0.01 ≤ P < 0.05; **, 0.001 ≤ P < 0.01; ***, P < 0.001. Results Establishment of a cisplatin-resistant cell line A CDDP-resistant subline (HT1376-CR) was established from the parental HT1376 (HT1376/P) bladder cancer cell line by gradually increasing the CDDP concentration during culture. The resulting HT1376-CR cells exhibited reduced sensitivity to CDDP, with a half-maximal inhibitory concentration (IC 50 ) more than threefold higher than that of parental HT1376/P cells ( Fig 1a ). HT1376-CR cells also demonstrated increased proliferative capacity, with a faster growth rate than HT1376/P cells ( Fig 1b ). The individual experimental data underlying Figs 1 – 5 are provided in S1 File . Download: PNG larger image TIFF original image Fig 1. Comparison of CDDP sensitivity and proliferation between HT1376/P and HT1376-CR. (a) Cell viability of HT1376/P and HT1376-CR cells following CDDP treatment. The x-axis represents the CDDP concentration, and the y-axis represents the relative cell number normalized to the cell number at 0 nM. (b) Proliferation growth curves of HT1376/P and HT1376-CR cells. Values were normalized to the cell number at day 0 for each group. Statistical significance is denoted as follows: *, 0.01 ≤ P < 0.05. https://doi.org/10.1371/journal.pone.0361593.g001 Download: PNG larger image TIFF original image Fig 2. Comparison of EV sensitivity between HT1376/P and HT1376-CR. (a) Cell viability of HT1376/P and HT1376-CR cells in response to EV treatment. The x-axis represents the drug concentration, and the y-axis indicates the relative cell number after exposure to the indicated drug concentrations. Values are normalized to the cell number at 0 nM. (b) Mean tumor volumes of HT1376/P xenografts treated with EV (HT1376/P-EV) or vehicle (HT1376/P-vehicle) and HT1376-CR xenografts treated with EV (HT1376-CR-EV) or vehicle (HT1376-CR-vehicle) at the indicated time points during EV treatment. (c) Representative macroscopic appearance of xenograft tumors after 21 days of EV treatment. (d) Relative tumor volume at day 22, calculated by normalizing tumor volume to baseline. Statistical significance is denoted as follows: *, 0.01 ≤ P < 0.05; ***, P < 0.001. https://doi.org/10.1371/journal.pone.0361593.g002 Download: PNG larger image TIFF original image Fig 3. Comparison of nectin-4 expression and EV binding between HT1376/P and HT1376-CR. (a) Immunoblot analysis of nectin-4 expression in HT1376/P and HT1376-CR cells. β-actin was used as the loading control. (b) Quantification of relative nectin-4 protein levels by immunoblot analysis. (c) Representative flow cytometry histograms showing cell-surface nectin-4 expression in HT1376/P and HT1376-CR cells. (d) Quantification of relative cell-surface nectin-4 expression measured by flow cytometry. (e) Representative flow cytometry histograms showing EV binding to HT1376/P and HT1376-CR cells. (f) Quantification of relative EV binding measured by flow cytometry. Statistical significance is denoted as follows: ***, P < 0.001. The original immunoblot images are provided in S2 File . https://doi.org/10.1371/journal.pone.0361593.g003 Download: PNG larger image TIFF original image Fig 4. Comparison of sensitivity to MMAE and cell cycle distribution between HT1376/P and HT1376-CR. (a) Cell viability of HT1376/P and HT1376-CR cells following MMAE treatment. The x-axis represents the concentration of MMAE, whereas the y-axis represents the relative cell viability 3 days after treatment, normalized to the value at 0 nM. (b, e) Representative histograms of cell cycle analysis for HT1376/P cells treated with MMAE at 0 nM (b) and 2 nM (e). (d) Quantification of the cell cycle distribution in HT1376/P and HT1376-CR cells treated without MMAE. (c, f) Representative histograms of cell cycle analysis in HT1376-CR cells treated with MMAE at 0 nM (c) and 2 nM (f). (g) Quantification of cell cycle distribution in HT1376-CR and HT1376-CR cells treated with MMAE at 2 nM. Statistical significance is denoted as follows: ns, ≥ 0.05; *, 0.01 ≤ P < 0.05. https://doi.org/10.1371/journal.pone.0361593.g004 Download: PNG larger image TIFF original image Fig 5. Comparison of ABC transporter expression and the impact of ABCB1 knockdown on drug sensitivity in HT1376-CR. (a) Quantitative PCR analysis of ABC transporter isoform expression in HT1376/P and HT1376-CR cells. Expression levels were normalized to β-actin and are presented as fold change relative to HT1376/P cells. (b) Immunoblot analysis of ABCB1 expression in HT1376/P and HT1376-CR cells. β-actin was used as the loading control. (c) Immunoblot analysis of ABCB1 expression in HT1376-CR with ABCB1 knockdown (KD1/2) and control. (d–f) Cell viability of ABCB1-knockdown and control HT1376-CR cells following treatment with CDDP (d), MMAE (e), EV (f). Statistical significance is denoted as follows: ns, ≥ 0.05; *, 0.01 ≤ P < 0.05; **, 0.001 ≤ P < 0.01; ***, P < 0.001. The original immunoblot images are provided in S2 File . https://doi.org/10.1371/journal.pone.0361593.g005 Comparison of enfortumab vedotin sensitivity between parental and cisplatin-resistant bladder cancer cell lines EV sensitivity was evaluated in HT1376/P cells and their CDDP-resistant counterparts. The CDDP-resistant cells exhibited markedly enhanced sensitivity to EV compared with the parental cells, showing lower viability across the tested concentration range ( Fig 2a ). We next examined whether this difference in EV sensitivity was also observed in vivo using a mouse xenograft model. Tumor growth curves demonstrated that EV treatment suppressed tumor growth in both HT1376/P and HT1376-CR xenografts ( Fig 2b , c ). To quantitatively compare treatment responses between tumor models, RTV was calculated by normalizing tumor volume to baseline ( Fig 2d ). Two-way ANOVA of log-transformed RTV values at day 22 revealed a significant interaction between tumor model and treatment (p = 0.039), indicating that the antitumor efficacy of EV differed between HT1376/P and HT137
## Related Clinical Research

- [Trastuzumab + nivolumab with gemcitabine–cisplatin as first-line therapy for HER2-positive unresec](https://medichelpline.com/clinical-feed/nature-3-trastuzumab-plus-nivolumab-with-gemcitabine-and-cisplatin-as-first-line-therapy.md)
- [Editorial placeholder: Innovative therapeutic approaches for complex cancers — source content miss](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-editorial-innovative-therapeutic-approaches-for-complex-cancers-exploring-new.md)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)
- [Checkpoint immunotherapy in gastrointestinal cancer — editorial (Volume II) overview](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-editorial-checkpoint-immunotherapy-reshaping-the-landscape-of-gastrointestinal.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.